IMVT Immunovant, Inc.
IMVT Immunovant, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $25.90 · VWAP $29.79 · -10.3% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, COO + 2 others sold $356.1K, Oct 5–9
Coverage
2 watchlists
IMVT Price Structure
Loading timeframes…
Peers
Every watchlist IMVT belongs to, members best 30-day change first — IMVT highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-scan
@monster-discoveries
Against street estimates
How IMVT's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about IMVT from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 8 days ago · Oct 9
- Immunovant Inc Stock Price Today | NASDAQ: IMVT Live - Investing.com
- Press Releases :: Immunovant, Inc. (IMVT)
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 :: Immunovant, Inc. (IMVT)
- Immunovant, Inc. (IMVT) 8-K Earnings Release - May 2026
- Immunovant (IMVT) Stock Price, Quote, News & History | Benzinga
IMVT research tape
67 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.